1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Pandemic Influenza-Pipeline Insights, 2017

Pandemic Influenza-Pipeline Insights, 2017

  • January 2017
  • -
  • Delve Insight


DelveInsight’s, “ Pandemic Influenza-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Pandemic Influenza. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Pandemic Influenza. DelveInsight’s Report also assesses the Pandemic Influenza therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Pandemic Influenza
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Pandemic Influenza pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Pandemic Influenza and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Pandemic Influenza-Pipeline Insights, 2017
Illustrative

- Pandemic Influenza Overview
- Pandemic Influenza Pipeline Therapeutics
- Pandemic Influenza Therapeutics under Development by Companies
- Pandemic Influenza Filed and Phase III Products
- Comparative Analysis
- Pandemic Influenza Phase II Products
- Comparative Analysis
- Pandemic Influenza Phase I and IND Filed Products
- Comparative Analysis
- Pandemic Influenza Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Pandemic Influenza - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Pandemic Influenza - Discontinued Products
- Pandemic Influenza - Dormant Products
- Companies Involved in Therapeutics Development for Pandemic Influenza
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Pandemic Influenza, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Pandemic Influenza Assessment by Monotherapy Products
- Pandemic Influenza Assessment by Combination Products
- Pandemic Influenza Assessment by Route of Administration
- Pandemic Influenza Assessment by Stage and Route of Administration
- Pandemic Influenza Assessment by Molecule Type
- Pandemic Influenza Assessment by Stage and Molecule Type
- Pandemic Influenza Therapeutics - Discontinued Products
- Pandemic Influenza Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Pandemic Influenza, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Pandemic Influenza Assessment by Monotherapy Products
- Pandemic Influenza Assessment by Combination Products
- Pandemic Influenza Assessment by Route of Administration
- Pandemic Influenza Assessment by Stage and Route of Administration
- Pandemic Influenza Assessment by Molecule Type
- Pandemic Influenza Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Influenza Diagnostics Market by Test type, Molecular, End user - Global Forecast to 2021

Influenza Diagnostics Market by Test type, Molecular, End user - Global Forecast to 2021

  • $ 5650
  • Industry report
  • February 2017
  • by MarketsandMarkets

The global influenza diagnostics market is expected to reach USD 767.4 million by 2021 from USD 508.0 million in 2016, at a CAGR of 8.6% from 2016 to 2021. On the basis of test type, the market is segmented ...

Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies

Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies

  • $ 4995
  • Industry report
  • January 2017
  • by GBI Research

Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies Summary Influenza, often referred to ...

H1N1 (Swine Influenza)- Market Insights, Epidemiology and Market Forecast-2023

H1N1 (Swine Influenza)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s H1N1 (Swine Influenza) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.